Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
Conditions
Giant Cell Arteritis (GCA)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Emory University School of Medicine: Division of Rheumatology, Atlanta, Georgia, United States
Contact: Principal Investigator (Athanasios Tiliakos, DO)Northwestern University, Chicago, Illinois, United States
Contact: Principal Investigator (Anisha Dua, MD)Johns Hopkins Hospital: Division of Rheumatology Vasculitis Center, Baltimore, Maryland, United States
Contact: Principal Investigator (Brendan Antiochos)Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Boston, Massachusetts, United States
Contact: Principal Investigator (Sebastian Unizony, MD)Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology, Great Neck, New York, United States
Contact: Principal Investigator (Lara El Khoury, MD)Hospital for Special Surgery, New York: Division of Rheumatology, New York, New York, United States
University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh, Pennsylvania, United States
Contact: Principal Investigator (Robyn E. Domsic, MD)
Study leads
Sebastian H Unizony, M.D.
Study Chair
Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases